Incyte (WBO:INCY) Cyclically Adjusted FCF per Share: €1.66 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:INCY Incyte Corp WBO:INCY
87 GF Score
Price €70.36
GF Value €60.38
! 4 Warning Signs
View Full Analysis

What is Incyte Cyclically Adjusted FCF per Share?

Incyte WBO:INCY 87 Cyclically Adjusted FCF per Share is €1.66 as of Mar. 2026. GuruFocus rates WBO:INCY with a GF Score™ of 87/100 and a GF Value™ of €60.38. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Incyte's adjusted free cash flow per share for the three months ended in Mar. 2026 was €1.481. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €1.66 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Incyte's average Cyclically Adjusted FCF Growth Rate was 41.40% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 26.60% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 82.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Incyte was 175.20% per year. The lowest was -11.60% per year. And the median was 11.35% per year.

As of today (2026-07-24), Incyte's current stock price is €70.36. Incyte's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €1.66. Incyte's Cyclically Adjusted Price-to-FCF of today is 42.39.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Incyte was 1631.50. The lowest was 36.22. And the median was 77.48.


Incyte  (WBO:INCY) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Incyte's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=70.36/1.66
=42.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Incyte was 1631.50. The lowest was 36.22. And the median was 77.48.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Incyte Cyclically Adjusted FCF per Share Related Terms


Incyte Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Incyte's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incyte Cyclically Adjusted FCF per Share Chart

Incyte Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.47 0.89 1.40 1.45 1.47

Incyte Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.82 1.64 1.55 1.47 1.66

WBO:INCY vs INSM, BNTX, ROIV: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Incyte's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incyte Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incyte's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Incyte's Cyclically Adjusted Price-to-FCF falls into.


WBO:INCY
87GF Score
Incyte Corp WBO:INCY
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Incyte Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Incyte's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.481/330.2130*330.2130
=1.481

Current CPI (Mar. 2026) = 330.2130.

Incyte Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.298 241.018 -0.408
201609 0.361 241.428 0.494
201612 0.381 241.432 0.521
201703 -0.932 243.801 -1.262
201706 0.374 244.955 0.504
201709 0.074 246.819 0.099
201712 -0.458 246.524 -0.613
201803 0.032 249.554 0.042
201806 0.086 251.989 0.113
201809 0.692 252.439 0.905
201812 0.238 251.233 0.313
201903 0.560 254.202 0.727
201906 0.430 256.143 0.554
201909 1.197 256.759 1.539
201912 0.421 256.974 0.541
202003 -3.018 258.115 -3.861
202006 0.908 257.797 1.163
202009 0.502 260.280 0.637
202012 0.210 260.474 0.266
202103 0.598 264.877 0.746
202106 0.398 271.696 0.484
202109 0.853 274.310 1.027
202112 0.323 278.802 0.383
202203 0.809 287.504 0.929
202206 0.687 296.311 0.766
202209 1.210 296.808 1.346
202212 1.101 296.797 1.225
202303 -0.549 301.836 -0.601
202306 1.224 305.109 1.325
202309 0.567 307.789 0.608
202312 0.589 306.746 0.634
202403 0.847 312.332 0.895
202406 -2.687 314.175 -2.824
202409 1.349 315.301 1.413
202412 1.680 315.605 1.758
202503 1.227 319.799 1.267
202506 0.112 322.561 0.115
202509 2.198 324.800 2.235
202512 2.177 324.054 2.218
202603 1.481 330.213 1.481

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €1.66 mean?
Incyte (WBO:INCY) has a Cyclically Adjusted FCF per Share of €1.66 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Incyte and its competitors.
Is Incyte's Cyclically Adjusted FCF per Share too high?
Incyte's current Cyclically Adjusted FCF per Share is €1.66. Overall, Incyte has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Incyte's Cyclically Adjusted FCF per Share compare to INSM and BNTX?
Incyte's Cyclically Adjusted FCF per Share of €1.66 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Incyte and its competitors. Incyte's current Cyclically Adjusted FCF per Share is €1.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incyte stock overvalued right now?
Incyte (WBO:INCY) has a current Cyclically Adjusted FCF per Share of €1.66. The stock's GF Value™ is €60.38, compared to a current price of €70.36 — trading 16.5% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €1.66. Incyte's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Incyte (WBO:INCY), the current Cyclically Adjusted FCF per Share is €1.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Incyte (WBO:INCY) Overvalued in 2026?

Based on GuruFocus' analysis, Incyte stock appears to be overvalued. The current stock price of €70.36 is trading 16.5% above its estimated GF Value™ of €60.38.

Key valuation signals for WBO:INCY:

  • Cyclically Adjusted FCF per Share: €1.66
  • GF Value™: €60.38 vs. price of €70.36 (16.5% above fair value)
  • GF Score™: 87/100 with 4 warning signs

No single metric tells the full story. See the WBO:INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Incyte Business Description

Address 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
87GF Score

Get the complete analysis for WBO:INCY

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€70.36
Price
€60.38
GF Value